EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Generating Control Groups for Organ Impairment Studies: A Case‐Study Comparing Statistical and Population Pharmacokinetic‐Based Matching Approaches

Jessica Barry iD, Sumit Bhatnagar iD, Wei Liu iD, Mohamed-Eslam F Mohamed iD

CPT: Pharmacometrics & Systems Pharmacology · 2026-01 · 15 (1)

DOI: 10.1002/psp4.70144 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, online erschienen am 14.11.2025. Verfasst von Jessica Barry und 3 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology, AbbVie Inc, North Chicago, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AbbVie Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A common challenge in conducting phase 1 studies that assess the impact of organ impairment on the pharmacokinetics of a drug is the recruitment of a demographically matched control group. The work presented here evaluated alternative approaches for generating control groups in these studies. Available phase 1 data from the upadacitinib and elagolix clinical programs were leveraged as case studies. A statistical matching approach and a population pharmacokinetic model‐based approach were evaluated retrospectively for these programs' hepatic and renal impairment clinical studies. Geometric mean ratios of logarithmically transformed C max and AUC inf were used to compare exposure in organ impairment groups to respective matched or virtual control groups. In the statistical matching approach, the genetic matching algorithm using Mahalanobis distance showed that external control groups were adequately demographically balanced across all impairment groups of the study except for age. A 3:1 k‐match approach minimized the prediction error between matched and reference in‐study results for both case studies, resulting in differences in geometric mean ratios ranging from −19% to 3% and −27% to 40% for upadacitinib and elagolix, respectively, compared to in‐study controls. Similarly, the population pharmacokinetic approach used models developed from phase 1 data in healthy participants and found that the results were generally comparable to the in‐study results, with differences in geometric mean ratios ranging from −30% to 17% and −24% to 41% for upadacitinib and elagolix, respectively. These analyses demonstrate that both approaches may be viable alternatives to assess the impact of organ impairment on pharmacokinetics.

Schlagwörter

Stichwörter der Autor:innen

hepatic impairmentrenal impairmentstatistical matchingvirtual control

Autor:innen und Institutionen

  • Clinical Pharmacology, AbbVie Inc, North Chicago, USA.

ORCID-Profile: Jessica Barry, Sumit Bhatnagar, Wei Liu, Mohamed-Eslam F Mohamed

Förderung

  • AbbVie Inc

Zitieren

APA

Barry, J., Bhatnagar, S., Liu, W., & Mohamed, M. F. (2026). Generating Control Groups for Organ Impairment Studies: A Case‐Study Comparing Statistical and Population Pharmacokinetic‐Based Matching Approaches. CPT: Pharmacometrics & Systems Pharmacology, 15(1). https://doi.org/10.1002/psp4.70144

Vancouver

Barry J, Bhatnagar S, Liu W, Mohamed MF. Generating Control Groups for Organ Impairment Studies: A Case‐Study Comparing Statistical and Population Pharmacokinetic‐Based Matching Approaches. CPT: Pharmacometrics & Systems Pharmacology. 2026;15(1). doi:10.1002/psp4.70144

BibTeX
@article{Barry2026,
  author = {Barry, Jessica and Bhatnagar, Sumit and Liu, Wei and Mohamed, Mohamed-Eslam F},
  title = {Generating Control Groups for Organ Impairment Studies: A Case‐Study Comparing Statistical and Population Pharmacokinetic‐Based Matching Approaches},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2026},
  volume = {15},
  number = {1},
  doi = {10.1002/psp4.70144}
}
Kostenlos starten →